Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Check # 205, somebody dropped 1.42 Mil at market for .010759. You have to be nuts or you should have 100's of Mils shares to do it.
Meta good report. NSAV.
Bid 11, Ask 16, Price 8 = MANIPULATION.
What can we do about it? Can we fight it? Sitting and doing nothing is not the option.
Yes, another great day for manipulators. NSAV.
If both sides are willing to do a deal in principal they should be able to agree.
BW LEASING DEAL WITH AN OPTION TO BUY.
Would be NSAV able and willing to do something like this. Could be structured in a different ways where NSAV could get part of the revenues and portion of this could be used toward the purchase price. Revenues could be an indicator for the purchase price agreeable to both sides and finalised at the later time. Just asking.
We/NSAV need a much better exposure IMO.
Halberd CEO Letter . Press Release | 04/25/2022
Jackson Center, Pennsylvania--(Newsfile Corp. - April 25, 2022) - Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC: HALB)
This past quarter has witnessed some very significant technical and organizational achievements by the Halberd team.
Q1 OVERVIEW AND ACHIEVEMENTS
Halberd demonstrated elimination of the final two of the "Top Ten" antigens linked to neurodegenerative diseases.
Halberd demonstrated that its antigen elimination process is able to selectively eliminate target antigens from cerebral spinal fluid (CSF).
Halberd investigations revealed that it's proprietary Covid-19 antibody demonstrated a high affinity to the Covid Omicron variant - the only antibody among six competitive antibodies tested which binds to Covid-19, the Delta variant and the Omicron variant.
Halberd added a microbiology expert, Dr. Chester Cooper, to its advisory staff to guide and advance the company's investigations into the extracorporeal elimination of E. coli bacteria, which is responsible for hundreds of thousands of deaths in the US from meningitis and blood sepsis.
Halberd added Dr. Ravi Durvasula, a renowned infectious disease specialist, to its advisory staff to help guide Halberd through the next development stages of the application of its technology - animal testing and human clinical trials.
Halberd successfully completed the audit of its financials and is awaiting sign-off of the completed Form 10 by the auditor. Form 10 will be filed immediately after sign-off.
2Q GOALS
Complete the addition of a DVM/PhD candidate to plan and execute extensive animal testing of Halberd's patented extracorporeal process for the removal of targeted disease antigens.
Complete the research of the removal of select target antigens from blood serum.
Complete and publish a scientific article on our revolutionary R&D achievements.
Contact select Big Pharma candidates for the purposes of exploring potential joint venture opportunities.
Develop program with NFL Retired Players' Association President seeking to secure NFL support/endorsement of our R&D into finding cures/treatments for traumatic brain injury TBI/ chronic traumatic encephalopathy (CTE) leading to potential neurodegenerative diseases in life after football.
Work with NCAA contacts seeking their support/endorsement of our R&D into finding cures/treatments for traumatic brain injury TBI/ chronic traumatic encephalopathy (CTE).
Develop plans for initiation of animal testing of our R&D for cures/treatments for TBI/CTE.
Initiate testing of Halberd's patent pending chemical bonding process for extracorporeal elimination of select disease antigens from bodily fluids, which would eliminate the need for laser or radio frequency irradiation.
Evaluate potential organizational changes which would allow Halberd to better focus on simultaneous R&D programs with different technologies.
Continue efforts to evaluate potential NFT program involving Halberd's technology.
Improve communication of Halberd's technology to the public via various media channels.
Evaluate Contract Research Organizations (CRO) to assist in scoping out the costs and timing of activities directed at obtaining FDA certification.
Contact FDA to establish potential for Emergency Use Authorization of Halberd's technology for select conditions and afflictions.
SUMMARY
Halberd continues to make great strides in its research and development of its patented extracorporeal process to treat a wide variety of diseases without the dangerous side-effects often associated with ingested or injected drugs used in conventional treatment methods. Our testing to date continues to demonstrate the superiority of our technology.
Our stated goals are real and reflect our confidence in achieving, or exceeding the desired results. We appreciate the efforts of our expanding team of research scientists, and the support of our stockholders. We will continue to maintain transparency and regular communication with interested parties.
Sincerely,
William A. Hartman
Chairman, President & CEO
HALBERD CORPORATION
w.hartman@halberdcorporation.com;
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC
About Halberd Corporation.
Halberd Corporation (the "Company") is an innovative biotech company focused on developing treatments through its acquired exclusive licenses, patents, and provisional patent applications for illnesses including and limited to; PTSD, CTE, cancer, blood-borne, and cerebrospinal fluid related diseases. To learn more, please visit https://halberdcorporation.com.
Halberd has obtained exclusive worldwide rights to three issued patents and has filed twenty related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/121486
In the 1st 3 Mo's of this year to be correct. NSAV.
But today shorts and their MM's participant are making the whether for NSAV. One day we'll put them down where they belong.
Agree and done.
So are you saying the PPS dropping was because of some selling done? What about naked short selling?
Not me. If anything positive is coming out of it I would treat it as positive surprise. NSAV still has a few good ingredients in the soup. :)
I would love to have 10 Mil for flipping.
Announcing not finalized deals is misleading and should be stopped. Only damaging credibility and doesn't do anything good for investors. At least should say "working on possible deal" imo. NSAV.
Agree again. $$$NSAV$$$
I agree.
Totally agree. DEFENCE< DEFENCE< DEFENCE!!!
LOL. NSAV.
Any good news? NSAV.
Actually I always have a trust in the company. It's like having grandkids you still worry about them and your kids in addition too. I care about my company in which I have full trust, but may be you have to be grandparent to get it. :)
Performance of the stock is the best stock advertisement. Over wise it's the laughable nonnesense.
Nagrom 10 you said it: "Anyone that looks at our stock’s performance will immediately say no to promoting it. We have dropped over 91%, since August."
And no positive posting is going to lift it up IMO. Tell them BUY BACK NOW!
HA HA. :(
Shorters paradise. NSAV.
Congrats. :(
Twice the average market volume today.
So in your opinion is anything NSAV can do to protect their shareholders right now? Apparently signing papers right now for the future is not helping.
And do they have enough financial back up to survive in this situation?
And lastly are the keeping an eye on competition?
Life time yes. NSAV.
"Many people are confused by Halberd's numerous announcements regarding its successes in eliminating various target disease antigens. Contrary to popular belief, we are not indiscriminately jumping from disease to disease. All of our work revolves around verifying that our underlying patented extracorporeal treatment technology is effective against a broad range of disease antigens. We are proving that the process can be used to successfully eliminate an extensive list of disease antigens, in a fraction of the time, and without dangerous drug-induced side-effects often associated with conventional drug treatments."
No fun at all. NSAV.
Then we will have another short to worry about.
At this point I have concerns and big ones here.
It doesn't matter if we are on the list or not. Our stock is still fully controlled by manipulators/sellers/mm's.
Nagrom10, my follow up to you for making this call and posting info. Good job!
HAPPY HOLIDAYS TO ALL NSAV SHAREHOLDERS!!!
Just rebounding, imo.
Higher on Monday. $$$NSAV$$$.
I hope that the piss pot is the only thing they are missing. GLTA.